BCL2 and lung cancer: Studies have shown that ICT (MOL056) could act on the PI3K-AKT signaling pathway to down-regulate the expression of Bcl-2 and up-regulate Bax, which promotes the apoptosis of lung cancer cells in the TME, thereby achieving the purpose of treating lung cancer [47].